Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01409148 · ClinicalTrials.gov registry record · Phase 1
Radioimmunoimaging of AL Amyloidosis
A Phase 1 study of AL Amyloidosis, sponsored by University of Tennessee.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT01409148: Completed Phase 1 study of AL Amyloidosis, sponsored by University of Tennessee.
NCT01409148 is a Phase 1 study of AL Amyloidosis that has completed, run by University of Tennessee. The registered enrollment target is 38 participants, below the 422-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01409148, a Phase 1 study of AL Amyloidosis, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
Conditions Studied
Interventions
- BIOLOGICAL 124I-labeled monoclonal antibody Mu 11-1F4
Study Locations (1)
Tennessee
- University of Tennessee Medical Center - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2008-11 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
What the finished NCT01409148 record still lists
NCT01409148 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 422-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (91% lower).
The record links to 1 condition, with AL Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which 124I-labeled monoclonal antibody Mu 11-1F4 is the first listed.
NCT01409148 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT01409148 about?
NCT01409148 is a clinical study titled "Radioimmunoimaging of AL Amyloidosis". The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.
What is the current status of trial NCT01409148?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2008-11. Estimated completion is 2012-03.
What conditions does trial NCT01409148 study?
This clinical trial studies the following conditions: AL Amyloidosis.
What interventions are being tested in trial NCT01409148?
The interventions under investigation include: 124I-labeled monoclonal antibody Mu 11-1F4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01409148?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01409148 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AL Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01409148's enrollment target sits among peer trials
38 10th of 15 higher than 6 of 15 other AL Amyloidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other AL Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
-
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
RECRUITING · Phase 1
-
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
ACTIVE NOT RECRUITING · Phase 1
-
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RECRUITING
-
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia